Dermatome Electrical Stimulation on Individuals With Overweight and Class I Obesity

Not Applicable

Terminated

Conditions: Obesity

Interventions: Device: Transcutaneous electrical nerve stimulation (TENS)

Registration Number: NCT03261531

Lead Sponsor: Mayo Clinic

Brief Summary: Investigators are doing this research study to find out the effect of T6 dermatomal electrical stimulation (delivered by a Transcutaneous Electrical Nerve Stimulation (TENS) unit) on appetite and weight loss.

Detailed Description: Participants will be treated before and after two meals of the day with T6 dermatomal electrical stimulation delivered by a Transcutaneous Electrical Nerve Stimulation (TENS) unit. Participants will receive 15-minute T6 dermatome cutaneous stimulation with TENS unit applied immediately before ingestion of two of main meals of the day (breakfast and evening meal), and 60 minute stimulation applied immediately after ingestion of these meals. Participants will apply the stimulus four times daily for a treatment period of at least 3 months. Participants will keep a diary of weight once weekly and a weekly appetite record.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 7

Inclusion Criteria

Overweight and obese adults (BMI ≥25 kg/m2 and ≤34.99 kg/m2) residing within 125 miles of Mayo Clinic in Rochester, Minnesota; these will be otherwise healthy individuals with no unstable psychiatric disease and not currently on treatment for cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, neurological, or endocrine (other than hyperglycemia on diet) disorders.
Age: 18-65 years
Gender: Men or women. Women of childbearing potential will be using an effective form of contraception, and have negative pregnancy tests within 48 hours of enrollment and before each radiation exposure.
Subjects must have the ability to provide informed consent before any trial-related activities.

Eligible individuals will be asked to avoid taking additional medications and supplements for the duration of the study, unless reviewed and approved by the study team.

Exclusion Criteria

Abdominal surgery other than appendectomy, Caesarian section or tubal ligation
Positive history of chronic gastrointestinal diseases, systemic disease that could affect gastrointestinal motility, or use of medications that may alter gastrointestinal motility, appetite or absorption, e.g., Orlistat
Positive history of diabetes mellitus or use of hypoglycemic medications
Positive history of spinal cord injury and/or chronic back pain
Significant untreated psychiatric dysfunction based upon screening with the Hospital Anxiety and Depression Inventory (HAD) (12), a self-administered alcoholism screening test (AUDIT-C) (13), and the Questionnaire on Eating and Weight Patterns (binge eating disorders and bulimia) (14). If such a dysfunction is identified by a HAD score >11 or difficulties with substance or eating disorders, the participant will be excluded and given a referral letter to his/her primary care doctor for further appraisal and follow-up.
Intake of medication, whether prescribed or over the counter (except multivitamins), within 7 days of the study. Exceptions are birth control pill, estrogen replacement therapy, thyroxine replacement therapy, low dose analgesia or anti-inflammatory medications (Acetaminophen and Ibuprofen) and any medication administered for co-morbidities as long as they do not alter gastrointestinal motility including gastric emptying and gastric accommodation.
Subjects may also be excluded from participation for other factors at the discretion of the principal investigator.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Transcutaneous electrical nerve stimulation (TENS)	Transcutaneous electrical nerve stimulation (TENS)	Healthy volunteers who are overweight or have class I obesity will receive T6 dermatomal electrical stimulation via Transcutaneous electrical nerve stimulation (TENS)

Primary Outcome Measures

Name	Time	Method
Gastric Half-emptying Time (GE T 1/2)	At 3 months, approximately 2 hours after radiolabeled meal is ingested	The time for half of the ingested solids to leave the stomach
Change in Body Weight	Baseline, 3 months	Change in body weight will be measured in kilograms or pounds

Secondary Outcome Measures

Name	Time	Method
Fasting Gastric Volume by 99mTc-SPECT Imaging	At 3 months, approx 20 minutes after 99mTC injection	A noninvasive SPECT method will be used to measure gastric volume. Subjects will report to the clinic after an overnight fast. The first fasting scan will be obtained, and the study medication (99mTc) will be given subcutaneously. After 10 min, a 2nd fasting post medication scan will be obtained. Each scan requires about 9-12 min. Tomographic images of the gastric wall will be obtained throughout the long axis of the stomach using a dual-head gamma camera that rotates around the body. This allows assessment of the radiolabeled circumference of the gastric wall, rather than the intragastric content. Volume will be measured in mL.
Satiation Volume (Level 3)	Approximately 30 minutes after the liquid meal	Subjects will ingest a liquid nutrient drink at a rate of 120 mL every 4 minutes; the volume ingested at each level of fullness will be recorded. Participants record their sensations of fullness using a numerical scale from 0 to 5, with level 0 being no symptoms, level 3 corresponding to fullness sensation after a typical meal ("volume to fullness"), and level 5 corresponding to the maximum tolerated volume (MTV). Nutrient intake is stopped when subjects reach the score of 5.
Change in Fasting and Peak Postprandial Plasma Ghrelin at 3 Months	baseline, 90 minutes postprandially	Total ghrelin will be measured by a radioimmunoassay technique.
Change in Fasting and Peak Postprandial Glucagon-like Peptide-1 (GLP-1) at 3 Months	baseline, 90 minutes postprandially	Glucagon-like peptide-1 (GLP-1) will be measured by a radioimmunoassay technique.
Change in Fasting and Peak Postprandial Peptide Tyrosine Tyrosine (PYY) at 3 Months	baseline, 90 minutes postprandially	Peptide Tyrosine Tyrosine (PYY) will be measured by radioimmunoassay.
Postprandial Gastric Volume (Gastric Accommodation) by 99mTc-SPECT Imaging	At 3 months, approximately 30 min after liquid meal	A noninvasive SPECT method will be used to measure gastric volume after a liquid nutritional supplement meal. Subjects reported to the clinic after an overnight fast. 99mTC will be given by an intravenous injection in the forearm. The first fasting scan was obtained, and the study medication (99mTc) will be given subcutaneously. After 10 min, a 2nd fasting post medication scan was obtained, and the meal consumed; then two serial postprandial scans will be obtained. Each scan requires about 9-12 min. Tomographic images of the gastric wall will be obtained throughout the long axis of the stomach using a dual-head gamma camera that rotates around the body. This allows assessment of the radiolabeled circumference of the gastric wall, rather than the intragastric content. Volume will be measured in mL.
Change in Gastric Emptying Percentage	Day 1, 3 months	The time for gastric retention of ingested solids or liquid to leave the stomach, measured in percentage.
Mean Kcal Intake at Buffet Meal as a Measure of Appetite	At 3 months, approximately 30 minutes after the buffet meal	Assessment of kcal intake as a measure of appetite buffet meal to measure total caloric intake. 5 hours after ingesting 300 mL liquid nutrient as part of the gastric volume study, participants will be invited to eat, during a 30-minute period, a standard "free feeding" meal. The total amount of food consumed will be analyzed by the study dietitian.
Satiation Maximum Tolerated Volume (Level 5)	Approximately 30 minutes after the liquid meal	Subjects will ingest a liquid nutrient drink at a rate of 120 mL every 4 minutes; the volume ingested at each level of fullness will be recorded. Participants record their sensations of fullness using a numerical scale from 0 to 5, with level 0 being no symptoms, level 3 corresponding to fullness sensation after a typical meal ("volume to fullness"), and level 5 corresponding to the maximum tolerated volume (MTV). Nutrient intake is stopped when subjects reach the score of 5.
Change in Appetite Score	Baseline, 3 months	Ratings of appetite will be measured every 30 minutes between the time of ingestion of standard liquid breakfast and the start of the ad libitum meal. The appetite rating will be measured by 4- 100 mm long Visual Analog Scales (VAS). The VAS does not have any pre-set marks between the extremes of 0 for negative rating and 100 mm for positive rating. The investigator measures the mark made by the participant in mm and records this for the value. The overall appetite score will be calculated as the average of the four individual scores (satiety + fullness+100-prospective food consumption + hunger/4.